Logo image of COV.PA

COVIVIO (COV.PA) Stock Fundamental Analysis

EPA:COV - Euronext Paris - Matif - FR0000064578 - REIT - Currency: EUR

50.1  +0.24 (+0.48%)

Fundamental Rating

4

Taking everything into account, COV scores 4 out of 10 in our fundamental rating. COV was compared to 42 industry peers in the Diversified REITs industry. COV has a medium profitability rating, but doesn't score so well on its financial health evaluation. COV has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

In the past year COV was profitable.
In the past year COV had a positive cash flow from operations.
Of the past 5 years COV 4 years were profitable.
In the past 5 years COV always reported a positive cash flow from operatings.
COV.PA Yearly Net Income VS EBIT VS OCF VS FCFCOV.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B -1B

1.2 Ratios

The Return On Assets of COV (0.27%) is worse than 64.29% of its industry peers.
The Return On Equity of COV (0.83%) is worse than 64.29% of its industry peers.
COV has a Return On Invested Capital (3.14%) which is comparable to the rest of the industry.
The Average Return On Invested Capital over the past 3 years for COV is in line with the industry average of 3.66%.
The last Return On Invested Capital (3.14%) for COV is above the 3 year average (2.97%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 0.27%
ROE 0.83%
ROIC 3.14%
ROA(3y)-1.05%
ROA(5y)0.29%
ROE(3y)-3.48%
ROE(5y)0.76%
ROIC(3y)2.97%
ROIC(5y)2.68%
COV.PA Yearly ROA, ROE, ROICCOV.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10

1.3 Margins

Looking at the Profit Margin, with a value of 5.23%, COV is doing worse than 64.29% of the companies in the same industry.
COV's Profit Margin has declined in the last couple of years.
COV's Operating Margin of 61.20% is on the low side compared to the rest of the industry. COV is outperformed by 64.29% of its industry peers.
COV's Operating Margin has been stable in the last couple of years.
The Gross Margin of COV (76.74%) is comparable to the rest of the industry.
In the last couple of years the Gross Margin of COV has remained more or less at the same level.
Industry RankSector Rank
OM 61.2%
PM (TTM) 5.23%
GM 76.74%
OM growth 3Y-1.46%
OM growth 5Y-1.11%
PM growth 3Y-61.53%
PM growth 5Y-38.78%
GM growth 3Y-2.18%
GM growth 5Y-0.89%
COV.PA Yearly Profit, Operating, Gross MarginsCOV.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

1

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so COV is destroying value.
Compared to 1 year ago, COV has more shares outstanding
COV has more shares outstanding than it did 5 years ago.
COV has a better debt/assets ratio than last year.
COV.PA Yearly Shares OutstandingCOV.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
COV.PA Yearly Total Debt VS Total AssetsCOV.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B 25B

2.2 Solvency

Based on the Altman-Z score of 0.55, we must say that COV is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.55, COV is doing worse than 78.57% of the companies in the same industry.
The Debt to FCF ratio of COV is 27.72, which is on the high side as it means it would take COV, 27.72 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 27.72, COV is doing worse than 69.05% of the companies in the same industry.
COV has a Debt/Equity ratio of 1.14. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 1.14, COV is not doing good in the industry: 80.95% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.14
Debt/FCF 27.72
Altman-Z 0.55
ROIC/WACC0.56
WACC5.65%
COV.PA Yearly LT Debt VS Equity VS FCFCOV.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2B 4B 6B 8B 10B

2.3 Liquidity

COV has a Current Ratio of 0.96. This is a bad value and indicates that COV is not financially healthy enough and could expect problems in meeting its short term obligations.
With a decent Current ratio value of 0.96, COV is doing good in the industry, outperforming 69.05% of the companies in the same industry.
A Quick Ratio of 0.85 indicates that COV may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.85, COV is in the better half of the industry, outperforming 71.43% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.96
Quick Ratio 0.85
COV.PA Yearly Current Assets VS Current LiabilitesCOV.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

5

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 0.00% over the past year.
The Earnings Per Share has been decreasing by -3.39% on average over the past years.
COV shows a strong growth in Revenue. In the last year, the Revenue has grown by 22.79%.
Measured over the past years, COV shows a small growth in Revenue. The Revenue has been growing by 1.17% on average per year.
EPS 1Y (TTM)0%
EPS 3Y0.91%
EPS 5Y-3.39%
EPS Q2Q%5.69%
Revenue 1Y (TTM)22.79%
Revenue growth 3Y9.01%
Revenue growth 5Y1.17%
Sales Q2Q%-30.62%

3.2 Future

Based on estimates for the next years, COV will show a small growth in Earnings Per Share. The EPS will grow by 1.89% on average per year.
COV is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.79% yearly.
EPS Next Y7.5%
EPS Next 2Y1.92%
EPS Next 3Y1.89%
EPS Next 5YN/A
Revenue Next Year-0.42%
Revenue Next 2Y1.71%
Revenue Next 3Y4.79%
Revenue Next 5YN/A

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
COV.PA Yearly Revenue VS EstimatesCOV.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 200M 400M 600M 800M 1B
COV.PA Yearly EPS VS EstimatesCOV.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 1 2 3 4 5

5

4. Valuation

4.1 Price/Earnings Ratio

COV is valuated reasonably with a Price/Earnings ratio of 11.21.
Based on the Price/Earnings ratio, COV is valued a bit cheaper than 71.43% of the companies in the same industry.
COV's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 25.91.
Based on the Price/Forward Earnings ratio of 10.43, the valuation of COV can be described as reasonable.
61.90% of the companies in the same industry are more expensive than COV, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 21.85, COV is valued rather cheaply.
Industry RankSector Rank
PE 11.21
Fwd PE 10.43
COV.PA Price Earnings VS Forward Price EarningsCOV.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

The rest of the industry has a similar Enterprise Value to EBITDA ratio as COV.
COV's Price/Free Cash Flow is on the same level as the industry average.
Industry RankSector Rank
P/FCF 14.54
EV/EBITDA 17.11
COV.PA Per share dataCOV.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 20 40 60

4.3 Compensation for Growth

The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
PEG (NY)1.49
PEG (5Y)N/A
EPS Next 2Y1.92%
EPS Next 3Y1.89%

5

5. Dividend

5.1 Amount

With a Yearly Dividend Yield of 7.01%, COV is a good candidate for dividend investing.
COV's Dividend Yield is rather good when compared to the industry average which is at 6.82. COV pays more dividend than 80.95% of the companies in the same industry.
COV's Dividend Yield is rather good when compared to the S&P500 average which is at 2.36.
Industry RankSector Rank
Dividend Yield 7.01%

5.2 History

The dividend of COV decreases each year by -1.54%.
Dividend Growth(5Y)-1.54%
Div Incr Years1
Div Non Decr Years1
COV.PA Yearly Dividends per shareCOV.PA Yearly Dividends per shareYearly Dividends per share 2019 2020 2021 2022 2023 2024 2025 1 2 3 4

5.3 Sustainability

COV pays out 112.19% of its income as dividend. This is not a sustainable payout ratio.
DP112.19%
EPS Next 2Y1.92%
EPS Next 3Y1.89%
COV.PA Yearly Income VS Free CF VS DividendCOV.PA Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M -1B
COV.PA Dividend Payout.COV.PA Dividend Payout, showing the Payout Ratio.COV.PA Dividend Payout.PayoutRetained Earnings

COVIVIO

EPA:COV (5/23/2025, 1:09:33 PM)

50.1

+0.24 (+0.48%)

Chartmill FA Rating
GICS SectorReal Estate
GICS IndustryGroupEquity Real Estate Investment Trusts (REITs)
GICS IndustryDiversified REITs
Earnings (Last)02-19 2025-02-19/amc
Earnings (Next)07-21 2025-07-21
Inst Owners40.89%
Inst Owner ChangeN/A
Ins Owners0.2%
Ins Owner ChangeN/A
Market Cap5.59B
Analysts80
Price Target60.78 (21.32%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 7.01%
Yearly Dividend0.72
Dividend Growth(5Y)-1.54%
DP112.19%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.9%
PT rev (3m)-2.88%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)8.19%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-3.04%
Revenue NY rev (3m)-3.96%
Valuation
Industry RankSector Rank
PE 11.21
Fwd PE 10.43
P/S 4.3
P/FCF 14.54
P/OCF 5.7
P/B 0.68
P/tB 0.71
EV/EBITDA 17.11
EPS(TTM)4.47
EY8.92%
EPS(NY)4.81
Fwd EY9.59%
FCF(TTM)3.45
FCFY6.88%
OCF(TTM)8.78
OCFY17.53%
SpS11.66
BVpS73.72
TBVpS70.63
PEG (NY)1.49
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 0.27%
ROE 0.83%
ROCE 3.52%
ROIC 3.14%
ROICexc 3.24%
ROICexgc 3.29%
OM 61.2%
PM (TTM) 5.23%
GM 76.74%
FCFM 29.56%
ROA(3y)-1.05%
ROA(5y)0.29%
ROE(3y)-3.48%
ROE(5y)0.76%
ROIC(3y)2.97%
ROIC(5y)2.68%
ROICexc(3y)3.08%
ROICexc(5y)2.79%
ROICexgc(3y)3.11%
ROICexgc(5y)2.81%
ROCE(3y)3.32%
ROCE(5y)3%
ROICexcg growth 3Y12.16%
ROICexcg growth 5Y0.31%
ROICexc growth 3Y11.77%
ROICexc growth 5Y0.14%
OM growth 3Y-1.46%
OM growth 5Y-1.11%
PM growth 3Y-61.53%
PM growth 5Y-38.78%
GM growth 3Y-2.18%
GM growth 5Y-0.89%
F-Score7
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 1.14
Debt/FCF 27.72
Debt/EBITDA 10.32
Cap/Depr 519.44%
Cap/Sales 45.79%
Interest Coverage 250
Cash Conversion 107.61%
Profit Quality 564.76%
Current Ratio 0.96
Quick Ratio 0.85
Altman-Z 0.55
F-Score7
WACC5.65%
ROIC/WACC0.56
Cap/Depr(3y)709.28%
Cap/Depr(5y)708.5%
Cap/Sales(3y)50.08%
Cap/Sales(5y)56.76%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0%
EPS 3Y0.91%
EPS 5Y-3.39%
EPS Q2Q%5.69%
EPS Next Y7.5%
EPS Next 2Y1.92%
EPS Next 3Y1.89%
EPS Next 5YN/A
Revenue 1Y (TTM)22.79%
Revenue growth 3Y9.01%
Revenue growth 5Y1.17%
Sales Q2Q%-30.62%
Revenue Next Year-0.42%
Revenue Next 2Y1.71%
Revenue Next 3Y4.79%
Revenue Next 5YN/A
EBIT growth 1Y0.7%
EBIT growth 3Y7.42%
EBIT growth 5Y0.05%
EBIT Next Year9.26%
EBIT Next 3Y7.23%
EBIT Next 5YN/A
FCF growth 1Y-28.86%
FCF growth 3YN/A
FCF growth 5Y31.13%
OCF growth 1Y-4.37%
OCF growth 3Y12.5%
OCF growth 5Y4.86%